Cargando…
Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
INTRODUCTION: In the UK and Ireland, severe and complex obesity is managed in specialist weight management services (SWMS), which provide multicomponent lifestyle interventions to support weight loss, and use of medication if available. Liraglutide 3 mg (LIRA 3 mg) is an effective weight-loss medica...
Autores principales: | Papamargaritis, Dimitris, Al-Najim, Werd, Lim, Jonathan, Crane, James, Lean, Mike, le Roux, Carel, McGowan, Barbara, O'Shea, Donal, Webb, David, Wilding, John, Davies, Melanie J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044994/ https://www.ncbi.nlm.nih.gov/pubmed/32060156 http://dx.doi.org/10.1136/bmjopen-2019-034137 |
Ejemplares similares
-
The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
por: Alabduljabbar, Khaled, et al.
Publicado: (2022) -
Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?
por: Papamargaritis, Dimitris, et al.
Publicado: (2021) -
Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016) -
Liraglutide: another reason to target prediabetes?
por: Murphy, Conor F., et al.
Publicado: (2017) -
Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili, Heshma, et al.
Publicado: (2021)